Digitize the protocol. Actionable, step-by-step treatment pathways designed for the modern point-of-care workflow — no 100-page PDFs, no scrolling, no delays.
Endocrinology Pathways
Source: ADA Standards of Care 2025 · Updated Jan 2025
First-Line Therapy
A1C ≥ 7%Assess A1C and cardiovascular risk. Initiate Metformin 500 mg BID with meals + lifestyle modification (diet, exercise). Target A1C < 7.0% for most adults.
Escalation — Initiate GLP-1 RA
Add-on TherapyIf A1C remains above target after 3 months, initiate a GLP-1 Receptor Agonist. Preferred: Semaglutide (Ozempic) 0.25 mg SQ weekly. Consider cardiovascular benefit profile.
Titration
Weeks 4–8Increase Semaglutide to 0.5 mg weekly after 4 weeks based on tolerability. Titrate to 1 mg at week 8 if additional glycemic control is needed. Max dose: 2 mg weekly.
Monitoring
OngoingCheck renal function (eGFR, creatinine) at baseline and every 3–6 months. Monitor for GI side effects. Reassess A1C at 3 months. Adjust if eGFR < 30 mL/min.
Intensification
If A1C > 8%If A1C remains above target at maximum tolerated dose, consider adding basal insulin (Glargine 10 units QHS) or SGLT-2 inhibitor. Reassess cardiovascular and renal risk.
⚠️ Clinical Disclaimer
The pathways presented in the MedaDose Clinical Guidelines Hub are summaries intended for educational reference only. They do not supersede the clinical judgment of the treating physician or the official, full-text guidelines published by recognized medical societies (e.g., AHA, ADA, AAP, APA, CDC). Dosing recommendations may vary based on individual patient factors. Always verify with primary literature and consult a licensed clinician before making prescribing decisions.
In 2026, healthcare providers do not have 15 minutes to scroll through a 100-page PDF from a medical society while a patient is in the room. The average clinical encounter lasts 18 minutes. The average clinical guideline runs 80–200 pages. The math does not work — and patients pay the price.
Guidelines must be instantly accessible, visual, and integrated directly into the prescribing workflow. The MedaDose Clinical Guidelines Hub transforms dense, society-published protocols into rapid-access step-by-step algorithms — surfacing the exact information a provider needs at the exact moment they need it, without requiring them to leave the point of care.
Research consistently shows that it takes an average of 17 years for clinical evidence to reach everyday practice. This "knowledge translation gap" is one of the most persistent and costly failures in modern healthcare. Providers are not failing to read — they are failing to have access to synthesized, actionable information at the right moment.
MedaDose bridges this gap by turning dense guidelines into rapid-access algorithms, ensuring evidence-based dosing at the point of care. By digitizing the protocol — not just linking to it — we reduce the cognitive burden on clinicians and accelerate the adoption of best-practice medicine across every care setting, from academic medical centers to rural telehealth practices.
Endocrinology
ADA Standards of Care 2025
Cardiology
ACC/AHA 2023 Guidelines
Pediatrics
AAP Clinical Practice Guideline 2024
Psychiatry
APA Practice Guidelines 2024
Pharmacology
CDC Clinical Practice Guideline 2022
17 yrs
average time for evidence to reach clinical practice
BMJ 2011
18 min
average clinical encounter duration
JAMA 2023
100+
pages in a typical society guideline PDF
ADA / AHA
5
specialties covered in the MedaDose Guidelines Hub
MedaDose
Drug interaction checking, dosage conversion, Sig generation — all in one platform.